During the past decade, Kelsey-Seybold Clinic conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kelsey-Seybold Clinic" #1 sponsor was "M.D. Anderson Cancer Center" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Galapagos NV" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "Incyte Corporation" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kelsey-Seybold Clinic" #1 collaborator was "Gilead Sciences" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator, "Agency for Healthcare Research and Quality (AHRQ)" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "Baylor College of Medicine" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Kelsey-Seybold Clinic" are "Breast Cancer" (2 trials), "Crohn's Disease" (2 trials), "Myelofibrosis" (2 trials), "Nonalcoholic Steatohepatitis" (2 trials) and "Post Essential Thrombocythemia Myelofibrosis" (2 trials). Many other conditions were trialed in "Kelsey-Seybold Clinic" in a lesser frequency.

Most popular intervention types in "Kelsey-Seybold Clinic" are "Drug" (13 trials), "Behavioral" (4 trials), "Other" (4 trials), "Device" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "placebo" (3 trials), "Filgotinib" (2 trials), "Placebo to match SEL 18 mg" (2 trials) and "Placebo to match SEL 6 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kelsey-Seybold Clinic" are 22 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kelsey-Seybold Clinic". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 14 completed trials in Kelsey-Seybold Clinic, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Kelsey-Seybold Clinic, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".